AI-Powered Discovery of T-Cell-Receptor-Based Cancer Immunotherapies
In-house generation of massive TCR-target interaction datasets using cutting-edge
high-throughput screening techniques
In silico predictions of TCR-target interactions through deep learning models trained on our proprietary datasets
Discovery of novel tumour targets shared across patients and safe and effective target-specific TCRs
CEO and CO-FOUNDER
PhD in Molecular and Computational Oncology (University of Oxford, UK) and deep expertise in mathematical modelling and molecular biophysics. Previously worked at the World Health Organisation assessing cancer prevention strategies.
CTO and CO-FOUNDER
PhD in Bio-Inspired Computation (University of Birmingham, UK) and several years of hands-on experience building cutting-edge AI software tools across the space, media, automotive and marketing industries.
Principal Investigator at University of Oxford. World expert in wet-lab methods for high-throughput screening of TCR-target pairs. Published in high-profile journals such as Nature Immunology, Cell and PNAS.
Founding partner at Selvedge Venture. Ex-director of deep-tech venture investments at Leaps for Bayer. Extensive experience negotiating and managing AI-driven co-development partnerships in the biopharmaceutical industry.